Absci Corporation (ABSI)

Over the past six months, Absci's stock has experienced fluctuations and was impacted by earnings reports and corporate announcements. The stock traded between a high of $6.33 and a low of $2.01 over the past 52 weeks. In August 2025, Absci reported its Q2 financial results, with revenues of $0.59 million and a net loss of $30.6 million, also announcing the expansion of its AI Drug Discovery collaboration with Almirall and progress on its internal asset programs. In November 2025, Absci announced its Q3 earnings, reporting an EPS of -$0.20 and quarterly revenue of $0.38 million, highlighting progress in the development of ABS-201 and interim Phase 1 results for ABS-101. In December 2025, Absci reported new human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates the stem cell niche and announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. In February 2026, Absci's CEO sold 26,761 shares of the company's stock, and the share price was $2.52, representing a decline of 46.50% over the period from February 6, 2025.

Information directly detailing demand seasonality for Absci Corp.'s specific products and services is not explicitly available. Demand for Absci's services and the progression of its pipeline would likely be driven by pharmaceutical and biotech R&D cycles, clinical trial progress and results, partnership agreements, and overall biotech investment trends. Significant demand seasonality for its core services and pipeline products is unlikely in the same way a retail or consumer goods company might experience it.

Absci Corporation is a biotechnology company that uses AI and synthetic biology to accelerate drug discovery and development. Founded in 2011 and headquartered in Vancouver, Washington, Absci integrates AI with biological systems to create new therapeutics more rapidly and efficiently. The company operates in the biotechnology and pharmaceutical sectors, with core business segments including AI-Driven Drug Discovery and Synthetic Biology and Biomanufacturing. Absci is a clinical-stage biopharmaceutical company with a pipeline of AI-designed therapeutics, including ABS-101 for IBD, ABS-201 for hair regrowth, ABS-301 for immuno-oncology, and ABS-501 for oncology. The company collaborates with various entities for joint research and development activities.

Absci Corporation's headquarters are located in Vancouver, Washington, USA. The company also has AI Research Labs in New York City and Serbia, and an Innovation Center in Zug, Switzerland. Absci operates as a data-first generative AI drug creation company in the United States.

Absci's brand reputation is largely tied to its advancements in AI-driven drug discovery and its pipeline development. Strategic collaborations with entities like AMD and Owkin, along with the expanded collaboration with Almirall, have positively impacted its reputation. Promising preclinical and clinical progress, particularly with ABS-201, has generated positive sentiment. Analyst sentiment is positive, with a "Strong Buy" consensus rating. However, the company's financial performance, including missing revenue and EPS estimates, could be a point of concern for its reputation among some investors.

Absci Corporation's ownership structure includes institutional investors, individual investors (insiders), and public and other shareholders. Institutions hold a significant portion of the company, with 258 institutional owners and shareholders holding a total of 124,364,735 shares, representing 65% of the company. Major institutional owners include Fmr Llc, ARK Investment Management LLC, BlackRock, Inc., Redmile Group, LLC and Vanguard Group Inc. Individual ownership, including insiders, accounts for approximately 6.30% of shares outstanding, with Sean McClain, the founder and CEO, directly holding 5.8% of the total shares outstanding.